SO-8 Soluble programmed cell death ligand 1 associated with clinical outcome in gastric cancer patients treated with nivolumab: Blood based biomarker analysis of DELIVER trial (JACCRO-GC08AR)

H. Kawakami,Y. Sunakawa, E. Inoue, R. Matoba, K. Noda, T. Sato, C. Suminaka, Y. Sakamoto,R. Kawabata,A. Ishiguro,Y. Akamaru,Y. Kito,H. Yabusaki, J. Matsuyama, M. Takahashi, A. Makiyama, H. Hayashi,K. Chamoto, T. Honjo, K. Nakagawa,W. Ichikawa, M. Fujii

Annals of Oncology（2022）

引用 1|浏览0

暂无评分

摘要

The potential predictive value of soluble checkpoint molecules for immune checkpoint inhibitor has been shown in several malignancies including non-small cell lung cancer and renal cell carcinoma, but not in gastric cancer. We thus assessed the association of soluble PD-1 (sPD-1), soluble Programmed cell Death Ligand 1 (sPD-L1) and soluble Cytotoxic T-Lymphocyte-Associated protein 4 (sCTLA-4) with efficacy measures including survival in advanced gastric cancer patients treated with nivolumab monotherapy using blood samples collected from a prospective observational and translational study (DELIVER [JACCRO-GC08] trial).

查看译文

关键词

cell death ligand,gastric cancer patients,gastric cancer,biomarker analysis,nivolumab

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要